M40403

M40403

A small superoxide dismutase mimetic that removes superoxides, converting toxic free radicals into O2 and H2O2, which are decomposed by catalase. It is being developed as a co-therapy with IL-2 for managing skin and kidney cancers, and has favourable therapeutic effects in animal models of acute myocardial infarction, stroke, inflammatory bowel disease, rheumatoid arthritis, diabetic microangiopathies and septic shock.
 
Pros
Lower molecular weight than SOD; penetrates cells and membranes easily; more stable; longer half-life; does not trigger an immune response.
References in periodicals archive ?
The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation.
CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted Orphan Drug Designation for M40403 for the prevention of radiation -- or chemotherapy -- induced oral mucositis (OM) in cancer patients.
CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today that The Committee for Orphan Drug Products of the European Medicines Agency (EMEA) has granted Orphan Drug Designation for M40403 for the prevention of oral mucositis (OM) in head and neck cancer patients receiving radiotherapy.
Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic, M40403.
Adding M40403 to IL-2 treatment kept blood pressure normal, which enabled researchers to double the dose of IL-2 in animal tests.
The lead candidates from this family, M40403 and M40419, are being tested in clinical trials for acute pain and refractory hypotension.
Salvemini D, Mazzon E, Dugo I, Riley DP, Serriano L, Caputi AP, Cuzzocrea S (2001) Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic, M40403.
M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to selectively remove superoxide, a free radical that, in excess, has been shown to contribute to inflammatory pathways and to regulate cytokine release.
A superoxide dismutase (SOD) mimetic program consisting of two clinical-stage drug candidates, M40403 and M40419, and a library of 250 small molecules which have potential as novel therapeutic agents for the treatment of inflammatory diseases.
M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to replicate the action of natural SOD enzymes, and selectively remove excess superoxide.
M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to replicate the action of natural SOD enzymes, one of the body's primary defenses against free-radical damage to cells and tissues.
In addition, the company is planning to initiate Phase II studies of M40403, a novel anti-inflammatory agent, for the treatment of post-operative ileus and other inflammatory diseases.